If 23andMe Is Up for Sale, So Is All That DNA

23andMe is facing significant financial difficulties, with its stock on the verge of being delisted and the company having shut down its in-house drug-development unit. The company has also experienced several rounds of layoffs, and its entire board of directors recently quit, except for co-founder and CEO Anne Wojcicki. Wojcicki has stated that she is open to selling the company, which would put the genetic data of its 15 million customers up for sale. 23andMe's genetic data is considered its most valuable asset, containing sensitive and personal information about its customers. The company has been collecting this data for nearly two decades, but has struggled to prove its value. While the data has been used to connect long-lost relatives and help solve crimes, it has limited use for most consumers beyond providing information about their ancestry and traits. The potential sale of 23andMe raises concerns about how the company's DNA data will be used by new owners. This is a concern for anyone who has used the service, as the data could be used in ways that are not in the best interest of the customers. The company's financial struggles are partly due to its inability to demonstrate the value of collecting and analyzing genetic data. The sale of 23andMe could have significant implications for the use of genetic data and the privacy of its customers.